Breath Test Lung Cancer Screening In China

The first respiratory biopsy laboratory in China is officially located in Renji Hospital of Shanghai Jiaotong University School of Medicine. The establishment of the laboratory marks the first collaboration between China and the UK in the field of respiratory biopsy, a tumor screening technology. Have you ever considered breath test lung cancer screening in china? The laboratory, established for the first time in China, will be jointly conducted by Chinese and British experts to conduct clinical trials for early detection of lung cancer, which will help to improve the early diagnosis rate of patients with lung cancer and other related tumors, and improve the precision treatment, in order to reduce medical costs and resources and save more patients' lives. We have some breath test lung cancer screening going on right now.

At the signing ceremony, Professor Li Weiping, President of Yanji Hospital, and Ms. Zhou Kaixuan, Executive Director of Li Ka Shing Foundation, delivered speeches respectively. Leaders of the Chinese and British institutions signed the cooperation agreement together.

It is reported that breath biopsy is the first revolutionary technology to screen for tumors by detecting volatile breath gases. The researchers used a breath sampler similar to a "vacuum blood collection tube" to capture breath samples for a few minutes and a microchip chemical sensor to analyze volatile metabolic compounds from the whole body with high sensitivity and selectivity, which can be used for early detection and real-time monitoring of diseases. 

　　Wang Liwei, director of the Department of Oncology and head of the laboratory at Renji Hospital, said frankly that in recent years, the incidence of lung cancer in China has been increasing year by year, and has become the leading malignant tumor in terms of mortality. Breath biopsy can be a key tool for early detection of respiratory cancer, which can not only reduce the cost of medical treatment and save medical resources, but also improve the overall early diagnosis rate and survival rate of cancer patients. Dr. Wang also said that early and reliable disease detection is one of the most effective ways to support patients and control healthcare costs, and that respiratory biopsy is one of the methods that has the potential to solve this challenge. It is hoped that the collaboration will help advance the development of testing tools for the benefit of oncology patients in China and around the world. Scientists study breath test lung cancer screening in china.

　　Under the collaboration agreement, Renji Hospital will provide the laboratory space, complete equipment and professional research team. The UK partner institution will provide respiratory biopsy technology, including respiratory samplers, collection stations, analytical instruments, and the procedures and training needed to support the efficient operation of the laboratory. In addition to research, the laboratory will also support research and investigations in cancer and other areas.

　　Chris Hodkinson, the British project leader, also said that respiratory biopsy provides researchers and clinicians with critical information about disease activity, allowing disease to be detected at an early stage. It is believed that this collaboration with Renji Hospital in the field of related technology will help to promote the improvement of the technology, so that more patients can benefit.

　　It is reported that the laboratory is supported by the Li Ka Shing Foundation. Yanji Hospital and the British related institutions to open the first domestic respiratory biopsy laboratory, will be officially launched in three months to carry out clinical trials of early detection of lung cancer.

　　So, what is a breath biopsy?

　　Breath biopsy is a non-invasive method of detecting changes in volatile organic compounds (VOCs) by obtaining metabolomic substances from the patient's breath for early detection and real-time monitoring of disease activity, and is becoming a key tool for early diagnosis of disease.

　　Volatile organic compounds (VOCs) are gas-phase chemicals with high vapor pressure at room temperature. VOCs are part of the components of exhaled breath and represent the volatile components of metabolites. These are low molecular weight compounds produced by metabolism in the body and represent the endpoints of gene, transcription and protein expression. Diseases have a direct impact on the body's metabolism and may lead to a loss of metabolic homeostasis, triggering changes in the volatile organic compounds exhaled in the patient's breath, so monitoring fluctuations in metabolites provides an effective method for disease detection, diagnosis and monitoring of disease. With a completely non-invasive "breath biopsy", these VOCs can be used as biomarkers of disease for early detection, screening, diagnosis and precision medicine, including patient stratification for treatment selection and monitoring. Some experiments have argued breath test lung cancer screening.

　　The main advantages of VOCs for respiratory biopsy are: 1, VOCs are products of in vivo metabolic activity, and therefore they directly reflect the current status of cells, tissues and microorganisms, providing a rich source of valuable information about individual health; 2, the metabolic information collected during respiratory biopsy for VOC biomarker analysis provides researchers and physicians with The metabolic information from VOC biomarker analysis collected during respiratory biopsies offers researchers and physicians new possibilities beyond a purely genomic approach. Whereas genomic analysis mostly provides only macroscopic information about an individual, breath biopsy has the potential to revolutionize early diagnosis and precision medicine for diseases such as cancer;3 VOCs provide details of current disease activity, not just macroscopic information about disease susceptibility;4 and because breath sampling itself is non-invasive and sampling is completely non-invasive and painless, breath biopsies that are uncomfortable and potentially unpleasant are more suitable for diagnostic procedures. uncomfortable and potentially unpleasant diagnostic procedures, such as blood sampling and tissue biopsy, are more appropriate for patients. Of course, VOCs can also be obtained from other clinical samples such as urine, stool and saliva.